Searchable abstracts of presentations at key conferences in endocrinology

ea0011p608 | Neuroendocrinology and behaviour | ECE2006

Bone mass and metabolism in active acromegaly – no impact of gonadal status. a study of 73 patients

Fougner SL , Godang K , Ueland T , Schreiner T , Bollerslev J

Background: Growth hormone (GH) is known to have stimulatory effects on bone tissue through a complex interaction of GH, IGF-1 and IGFBPs. The gonadal status is also thought to influence bone metabolism. Bone mass in patients with acromegaly reflects the long-time effects of GH excess on bone. However, data on bone status in acromegaly have been conflicting.Objective: The object of the study was to examine the impact of chronic GH excess on bone mass and...

ea0026p192 | Pituitary | ECE2011

Adipocytes as a source of increased circulating levels of NAMPT/visfatin in active acromegaly

Olarescu C , Ueland T , Lekva T , Dahl T B , Aukrust P , Halvorsen B , Bollerslev J

Background: Nicotinamide phosphoribosyltransferase (NAMPT)/PBEF/visfatin is a widely expressed cytokine with various effects on glucose and lipid metabolism, cell survival, and inflammation. Despite a favorable body composition profile, acromegalic patients present insulin resistance, increased cardiovascular risk, and higher incidence of secondary tumors.Aim: Based on its relation to glucose and lipid metabolism and inflammation we hypothesized that NAM...

ea0029oc1.6 | Pituitary Clinical I | ICEECE2012

Normal weight adult patients with Prader–Willi syndrome are not protected from insulin resistance during treatment with GH: results from a 12 month prospective study

Jorgensen A. , Ueland T. , Sode-Carlsen R. , Schreiner T. , Rabben K. , Farholt S. , Hoybye C. , Christiansen J. , Bollerslev J.

Background: Diabetes mellitus is prevalent in adults with Prader–Willi syndrome (PWS), and GH therapy may deteriorate glucose balance.Design: We prospectively investigated effects of 12 months of GH treatment on body composition and insulin resistance in relation to BMI in forty-two adults, mean(±S.D.) age 28.5±6.7 years with genetically verified PWS. Three patients with known diabetes were excluded. Data from baseline and 1...